Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Novitium Pharma LLC
EIR
•Novitium Pharma LLC•May 9, 2018

Novitium Pharma LLC – FDA EIR, May 9, 2018

Record Details

An FDA pre-approval inspection was conducted at Novitium Pharma LLC in East Windsor, NJ, from May 2 to May 9, 2018. This inspection, following the regulatory framework for Drug Pre-approval Inspections, evaluated manufacturing processes, equipment, production, and analytical records for two Abbreviated New Drug Applications (ANDAs): Diazoxide Oral Suspension USP, 50 mg/mL, and another pending ANDA. While no FDA Form 483 (Inspectional Observations) was issued, the inspection identified several concerns discussed with company management. Key issues included potential cross-contamination risks associated with non-dedicated manufacturing equipment and incomplete cleaning validations for shared processing lines. The firm had not yet developed a comprehensive cleaning validation matrix based on product solubility and potency. Additionally, deficiencies were noted in Master Batch Records (MBRs), specifically that dispensing records only referenced internal material codes instead of full ingredient names, and mixing speed ranges were too broad to ensure effective process control. Novitium Pharma LLC was informed that the two ANDAs would be recommended for approval, subject to the FDA’s Center for Drug Evaluation and Research (CDER) final review. To address the identified issues, the company committed to revising MBR dispensing records to include ingredient names, tightening mixing speed controls and confirming them during process validation, completing product-specific cleaning validations before commercial manufacturing, and establishing a bioburden baseline. These actions are necessary to minimize contamination risks and ensure ongoing regulatory compliance.

Company
Novitium Pharma LLC
Inspection date
May 9, 2018
Product type
drugs
Office
New Jersey District Office
Person
  • Russell J. Glapion
View Company Profile

ID · 752cd802-342c-4c45-9c6a-e8167508d66f

Other documents for Novitium Pharma LLC
  • 483 - 2026-07-22July 22, 2026
  • 483 - 2021-07-08July 8, 2021
  • EIR - 2019-02-04February 4, 2019
  • 483 - 2019-02-04February 4, 2019
  • EIR - 2018-09-11September 11, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novitium Pharma LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.